Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US10823727B2 · kind B2 · utility
8Cited by
112References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2018 |
| Grant date | Nov 3, 2020 |
| Priority date | — |
| Expiry date | Nov 19, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.